Disposition of 3350 shares by Link William J Phd of Tarsus Pharmaceuticals subject to Rule 16b-3
| TARS Stock | USD 41.91 1.10 2.70% |
Slightly above 55% of Tarsus Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that some investors are interested at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Tarsus Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Tarsus Pharmaceuticals Fundamental Analysis
We analyze Tarsus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Tarsus Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Tarsus Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tarsus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Tarsus Pharmaceuticals Related Equities
| PHAT | Phathom Pharmaceuticals | 3.47 | ||||
| VIGL | Vigil Neuroscience | 0.12 | ||||
| VRCA | Verrica Pharmaceuticals | 1.24 | ||||
| IVA | Inventiva | 1.81 | ||||
| INBX | Inhibrx Biosciences, | 1.88 | ||||
| EWTX | Edgewise Therapeutics | 4.89 | ||||
| PRAX | Praxis Precision | 5.55 | ||||
| FDMT | 4D Molecular | 18.38 |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.